Cardiac Biotech Solutions Inc. (OTCPK: CBSC)
Health Care · Pharmaceuticals · US
$0.04
+16.24% today · -2.6% 1Y
Cardiac Biotech Solutions Inc. (OTCPK: CBSC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.48M and employs 4 people.
Over the last twelve months the share price has lost 2.6%, trading between 0.02 and 0.06.
Tweenvest scores Cardiac Biotech Solutions Inc. across four factors: quality 18/100, value 44/100. Its strongest factor is value.
CBSC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.48M
- Revenue (TTM)
- $50.37K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 1.95
- 52-week high
- $0.06
- 52-week low
- $0.02
- Avg volume (3M)
- —
- Shares outstanding
- 170.44M
- Employees
- 4
- Next earnings
- —
About Cardiac Biotech Solutions Inc.
Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.
- ISIN
- US12506E1038
- Listed since
- Feb 16, 2016
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.